Effects of ghrelin receptor agonist, relamorelin, on gastric motor functions and satiation in healthy volunteers.
Effects of ghrelin receptor agonist, relamorelin, on gastric motor functions and satiation in healthy volunteers.
复制标题
DOI：
10.1111/nmo.12870
复制
发表时间：
2016-11
影响因子：
3.5
通讯作者：
Burton D
中科院分区：
文献类型：
--
作者：
Nelson AD;Camilleri M;Acosta A;Busciglio I;Linker Nord S;Boldingh A;Rhoten D;Ryks M;Burton D
合成的人胃饥饿素加速胃排空，减少胃调节，并导致餐后症状评分的数值增加。生长激素释放肽受体激动剂瑞莫林可加速糖尿病胃轻瘫患者的胃排空。测量Relamorelin对健康志愿者胃适应性、远端胃窦运动和饱足的药理作用。在16名健康志愿者的安慰剂对照、双盲、随机化研究中，我们比较了30μg皮下（SQ）瑞莫林与安慰剂对以下方面的影响：1）通过SPECT测量的胃容积，2）通过15腔灌注胃十二指肠测压法测量的餐后1小时远端胃窦运动指数（MI），3）通过Ensure营养饮料试验测试的饱腹感。主要终点为：空腹和餐后胃容量、远端胃窦相位压力活动（收缩次数、平均振幅和MI）和最大耐受容量。结果呈正态分布，使用t检验比较两个治疗组。与安慰剂相比，Relamorelin（30µg SQ）显著增加了餐后0-60分钟内远端胃窦的收缩次数（p=0.022）;这也在前两个15分钟内观察到（收缩次数0-15和16-30的p=0.005和0.015）。MI 0 -15（p=0.055）出现临界增加，MI 0 -60（p=0.139）和MI 16 -30（p=0.116）在数值上增加。收缩幅度没有显著增加。Relamorelin没有显著改变空腹或餐后胃容量，胃适应性，或饱食量和症状。Relamorelin增加远端胃窦运动性收缩的频率，但对收缩幅度无显著影响。调节抑制的缺乏和饱食症状增加的缺乏支持瑞莫林用于治疗症状性胃轻瘫（ClinicalTrials.gov NCT 02466711）。在16名健康志愿者中，我们比较了30μg皮下（SQ）瑞莫林与安慰剂对以下方面的影响：1）通过SPECT测量的胃体积，2）通过15腔灌注胃十二指肠测压法测量的餐后1小时远端胃窦运动指数（MI），以及3）通过Ensure营养饮料试验测试的饱腹感。与安慰剂相比，Relamorelin（30µg SQ）显著增加了餐后0-60分钟期间远端胃窦的收缩次数（p=0.022）;这也在前两个15分钟期间观察到（收缩次数0-15和16-30分别为p=0.005和0.015）。Relamorelin增加远端胃窦运动性收缩的频率，但对收缩幅度无显著影响。调节抑制的缺乏和饱食症状增加的缺乏支持瑞莫林用于治疗症状性胃轻瘫。
Synthetic human ghrelin accelerates gastric emptying, reduces gastric accommodation, and results in numerical increases in postprandial symptom scores. The ghrelin receptor agonist, relamorelin, accelerates gastric emptying in patients with diabetic gastroparesis. To measure pharmacological effects of relamorelin on gastric accommodation, distal antral motility, and satiation in healthy volunteers. In a placebo-controlled, double-blind, randomized study of 16 healthy volunteers, we compared effects of 30µg subcutaneous (SQ) relamorelin to placebo on: 1) gastric volumes measured by SPECT, 2) 1-hour postprandial distal antral motility index (MI) by 15-lumen perfusion gastroduodenal manometry, and 3) satiation tested by Ensure nutrient drink test. Primary endpoints were: fasting and postprandial gastric volumes, distal antral phasic pressure activity (number of contractions, mean amplitude, and MI), and maximum tolerated volume. Results were normally distributed and the two treatment groups were compared using t-test. Relamorelin, 30µg SQ, significantly increased the number of contractions in the distal antrum during 0–60 minutes post-meal when compared to placebo (p=0.022); this was also observed in the first two 15minute periods (p=0.005 and 0.015 for number of contractions 0–15 and 16–30). There was borderline increase in MI0–15 (p=0.055) and numerically increased MI0–60 (p=0.139) and MI16–30 (p=0.116). The amplitude of contractions was not significantly increased. Relamorelin did not significantly alter fasting or postprandial gastric volumes, gastric accommodation, or satiation volumes and symptoms. Relamorelin increases frequency of distal antral motility contractions without significant effects on amplitude of contractions. The lack of inhibition of accommodation and absence of increase in satiation symptoms support relamorelin for the treatment of symptomatic gastroparesis (ClinicalTrials.gov NCT02466711). In 16 healthy volunteers, we compared effects of 30µg subcutaneous (SQ) relamorelin to placebo on: 1) gastric volumes measured by SPECT, 2) 1-hour postprandial distal antral motility index (MI) by 15-lumen perfusion gastroduodenal manometry, and 3) satiation tested by Ensure nutrient drink test. Relamorelin, 30µg SQ, significantly increased the number of contractions in the distal antrum during 0–60 minutes post-meal when compared to placebo (p=0.022); this was also observed in the first two 15 minute periods (p=0.005 and 0.015 for number of contractions 0–15 and 16–30). Relamorelin increases frequency of distal antral motility contractions without significant effects on amplitude of contractions. The lack of inhibition of accommodation and absence of increase in satiation symptoms support relamorelin for the treatment of symptomatic gastroparesis.
登录
查看更多内容
影响因子：
7.7
作者：
BUYSSCHAERT, M;DONCKIER, J;LAMBERT, AE
通讯作者：
LAMBERT, AE
影响因子：
29.4
作者：
Date, Y;Murakami, N;Nakazato, M
通讯作者：
Nakazato, M
DOI：
10.1111/j.1439-0442.2006.00787.x
发表时间：
2006-03-01
期刊：
JOURNAL OF VETERINARY MEDICINE SERIES A-PHYSIOLOGY PATHOLOGY CLINICAL MEDICINE
影响因子：
--
作者：
Burger, DM;Wiestner, T;Arnold, S
通讯作者：
Arnold, S
影响因子：
3.1
作者：
ABELL, TL;CAMILLERI, M;MALAGELADA, JR
通讯作者：
MALAGELADA, JR
影响因子：
29.4
作者：
Cremonini, Filippo;Camilleri, Michael;Zinsmeister, Alan R.
通讯作者：
Zinsmeister, Alan R.